rs117111131

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_194318.4(B3GLCT):​c.271-12T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0239 in 1,597,596 control chromosomes in the GnomAD database, including 579 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.019 ( 38 hom., cov: 28)
Exomes 𝑓: 0.024 ( 541 hom. )

Consequence

B3GLCT
NM_194318.4 intron

Scores

2
Splicing: ADA: 0.00008837
2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: -0.256

Publications

3 publications found
Variant links:
Genes affected
B3GLCT (HGNC:20207): (beta 3-glucosyltransferase) The protein encoded by this gene is a beta-1,3-glucosyltransferase that transfers glucose to O-linked fucosylglycans on thrombospondin type-1 repeats (TSRs) of several proteins. The encoded protein is a type II membrane protein. Defects in this gene are a cause of Peters-plus syndrome (PPS).[provided by RefSeq, Mar 2009]
B3GLCT Gene-Disease associations (from GenCC):
  • Peters plus syndrome
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet, G2P, PanelApp Australia

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.84).
BP6
Variant 13-31247011-T-C is Benign according to our data. Variant chr13-31247011-T-C is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 96625.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0186 (2812/151098) while in subpopulation NFE AF = 0.0263 (1787/67856). AF 95% confidence interval is 0.0253. There are 38 homozygotes in GnomAd4. There are 1293 alleles in the male GnomAd4 subpopulation. Median coverage is 28. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 38 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
B3GLCTNM_194318.4 linkc.271-12T>C intron_variant Intron 4 of 14 ENST00000343307.5 NP_919299.3 Q6Y288

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
B3GLCTENST00000343307.5 linkc.271-12T>C intron_variant Intron 4 of 14 1 NM_194318.4 ENSP00000343002.4 Q6Y288

Frequencies

GnomAD3 genomes
AF:
0.0186
AC:
2814
AN:
150988
Hom.:
38
Cov.:
28
show subpopulations
Gnomad AFR
AF:
0.00526
Gnomad AMI
AF:
0.0175
Gnomad AMR
AF:
0.0216
Gnomad ASJ
AF:
0.0737
Gnomad EAS
AF:
0.000394
Gnomad SAS
AF:
0.00526
Gnomad FIN
AF:
0.0123
Gnomad MID
AF:
0.0223
Gnomad NFE
AF:
0.0263
Gnomad OTH
AF:
0.0252
GnomAD2 exomes
AF:
0.0214
AC:
5368
AN:
251274
AF XY:
0.0217
show subpopulations
Gnomad AFR exome
AF:
0.00418
Gnomad AMR exome
AF:
0.0172
Gnomad ASJ exome
AF:
0.0718
Gnomad EAS exome
AF:
0.0000544
Gnomad FIN exome
AF:
0.0160
Gnomad NFE exome
AF:
0.0282
Gnomad OTH exome
AF:
0.0294
GnomAD4 exome
AF:
0.0245
AC:
35404
AN:
1446498
Hom.:
541
Cov.:
31
AF XY:
0.0245
AC XY:
17636
AN XY:
720648
show subpopulations
African (AFR)
AF:
0.00488
AC:
162
AN:
33182
American (AMR)
AF:
0.0176
AC:
786
AN:
44692
Ashkenazi Jewish (ASJ)
AF:
0.0759
AC:
1977
AN:
26040
East Asian (EAS)
AF:
0.0000505
AC:
2
AN:
39598
South Asian (SAS)
AF:
0.00786
AC:
675
AN:
85924
European-Finnish (FIN)
AF:
0.0159
AC:
846
AN:
53316
Middle Eastern (MID)
AF:
0.0285
AC:
164
AN:
5748
European-Non Finnish (NFE)
AF:
0.0266
AC:
29246
AN:
1098148
Other (OTH)
AF:
0.0258
AC:
1546
AN:
59850
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.453
Heterozygous variant carriers
0
1478
2956
4435
5913
7391
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
1076
2152
3228
4304
5380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0186
AC:
2812
AN:
151098
Hom.:
38
Cov.:
28
AF XY:
0.0175
AC XY:
1293
AN XY:
73802
show subpopulations
African (AFR)
AF:
0.00524
AC:
216
AN:
41188
American (AMR)
AF:
0.0215
AC:
324
AN:
15104
Ashkenazi Jewish (ASJ)
AF:
0.0737
AC:
255
AN:
3460
East Asian (EAS)
AF:
0.000395
AC:
2
AN:
5064
South Asian (SAS)
AF:
0.00527
AC:
25
AN:
4748
European-Finnish (FIN)
AF:
0.0123
AC:
128
AN:
10386
Middle Eastern (MID)
AF:
0.0240
AC:
7
AN:
292
European-Non Finnish (NFE)
AF:
0.0263
AC:
1787
AN:
67856
Other (OTH)
AF:
0.0249
AC:
52
AN:
2088
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
127
254
382
509
636
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
34
68
102
136
170
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0274
Hom.:
9
Bravo
AF:
0.0199
Asia WGS
AF:
0.00462
AC:
16
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Peters plus syndrome Benign:3
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 29, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not specified Benign:2
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 18, 2013
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jul 05, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.84
CADD
Benign
0.020
DANN
Benign
0.70
PhyloP100
-0.26
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.000088
dbscSNV1_RF
Benign
0.0020
SpliceAI score (max)
0.17
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs117111131; hg19: chr13-31821148; API